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Title:​ ADHD: A Reflection of Increased Medicalization in America? 
Abstract: 
Medicalization in the United States has created more consistent classification and 
treatment guidelines for disorders and diseases nation-wide. However, the concept may foster a 
tendency toward premature diagnosis. The same can be said about pharmaceuticalization and 
quickness to medicate. Drug innovation and administration can be integral to quality of life, but 
how does this relationship shift when health becomes a commodity? How can the business end 
of medicine and pharmacy conflict with ethical responsibilities to patients? Here I utilize the 
increase in American Attention Deficit Hyperactivity Disorder diagnoses and psychostimulant 
prescriptions to illustrate potential repercussions of an increasingly medicalized and 
pharmaceuticalized society. I argue that the premature prescription of medication in response to 
rising ADHD diagnoses is an unethical course of treatment, thereby impeding the identification 
of the true causes underlying the symptoms and exposing the patient to unnecessary drug risks 
and side effects as a reflection of commercialized health.  
Introduction 
Over the past few decades, the number of Attention Deficit Hyperactivity Disorder 
(ADHD) diagnoses in America has increased significantly. Following this trend is an increase in 
the medicalization of behavioral variation in children; but is this an acceptable reason to 
medicate? Medicalization is the process by which human conditions become defined and treated 
as medical issues (Maturo, 2012). Reliance on medication for clinical treatment reflects the 
tremendous growth of the pharmaceutical industry. Pharmacological interventions mitigate 
conditions that were once treated with therapy alone, and have fostered an increased reliance on 
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medication. This is a result of pharmaceuticalization, which is the process of pharmacologically 
intervening in human conditions (Williams, 2011). The DEA reported a 40% increase in the 
number of prescription stimulants distributed for ADHD in America between 2007 and 2011 
alone (Lautieri, 2019). It is imperative to identify whether this medicational surge is due to 
physiological cases, the changing social definition of ADHD and what it means to be 
“abnormal,” or the desire for a quick fix to more serious underlying issues. The purposes of this 
paper are to: 1) examine the cause behind increased number of ADHD psychostimulant 
prescriptions in the United States; and 2) determine if and when psychostimulants are warranted.  
Definitions of ADHD Over Time 
In a 1940s study, the most common teachers’ complaints about their students were 
chewing gum, running in the halls, and talking out of turn (Franklin, 2016). Today, complaints 
have shifted toward class disruptions, lack of motivation, and a general disinterest in learning. 
But is the classroom environment so different today? Or have these behaviors been present all 
along, but never recognized as undesirable?  
Perhaps the answer lies in how we diagnose ADHD, and how it compares to the societal 
perception of “normal.” In the DSM-2 from 1968, there was no such thing as ADHD. Instead, 
there was “hyperkinetic disease” characterized by extreme fidgeting and inability to sit still in 
infants and young children, and encompassed everything from restlessness to severe autism 
(Lange, 2010). Not until the release of the DSM-3 in 1980 was the term Attention Deficit 
Disorder, or ADD, first introduced. This was described as recurrent problems with impulse 
control and attention, and included versions with and without hyperactivity. Finally, the term 
ADHD appeared in the DSM-4 in 1994, and again with more detail in the 2013 DSM-5. 
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However, even the slightest changes in phraseology have drastically different implications. A 
small semantic revision between the 1980 DSM-3 definition and the 1987 definition resulted in a 
50% increase in child ADHD diagnoses (Moynihan, 2005). And while the DSM-4 required 
functional impairments to be “clinically significant” to be categorized as ADHD, the DSM-5 
only requires that they “​reduce the quality of​ social, academic or occupational functioning​” 
(Epstein, 2013). The broadening parameters of ADHD classification over time factor into the 
increased diagnoses we see today. Once normal behaviors are now seen as symptoms of a 
disorder, and in many cases result in daily drug use to compensate.  
ADHD Drugs and their Mechanisms of Action 
Medications used to treat ADHD are categorized as psychostimulants, which excite the 
central nervous system and increase attention and alertness (Favrod-Coune, 2010). They are used 
to treat other conditions such as depression, narcolepsy, and epilepsy (Mohamed, 2012). The 
psychostimulants most commonly used to treat ADHD are Ritalin (methylphenidate) and 
Adderall (amphetamine). These drugs work by inhibiting norepinephrine and dopamine 
transporters in the brain to increase its extracellular hormone levels, specifically in the prefrontal 
cortex (Spencer, 2015). The prefrontal cortex is involved in functions from attention and 
memory to speech, self-control, and abstract thinking (Siddiqui, 2008). But what are the 
medication’s long-term effects on such a fundamental brain area?  
A 2013 study found that psychostimulants increased the number of dopamine transporters 
in the brains of ADHD patients over time. These effects were observed as early as just one year 
after the start of daily use (Wang, 2013). Decreased levels of dopamine in the brain are 
associated with other conditions such as depression or anxiety. Consequently, long-term use of 
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psychostimulants could foster development of other mental health issues. Furthermore, the 
increase in dopamine transporters results in a need for increased medication dosage to maintain 
the same level of cognitive effect on the patient over time. Even guidelines from the ​American 
Academy of Child and Adolescent Psychiatry​ recognize that ​“most [children] require dose 
adjustment upward as treatment progresses” (Pliszka, 2007). While it is true that the AACAP 
mainly refers to the early stages of diagnosis in which each patient is started on the minimal 
dosage and gradually increased to their optimal level, it does not necessarily follow that dosage 
increases stop there. ​Many 6-year-old patients starting out at 5 milligrams of Adderall a day can 
have their dosages increased to 20-30 milligrams by adolescence (Huss, 2017). 
Discussion 
Influence of Pharmacological Commercialization 
The surge in ADHD psychostimulant prescriptions exemplifies a larger trend of 
American dependence on pharmacology. Underperformance, inattentiveness, and hyperactivity 
across a broader range of age and social contexts are lumped together and treated under the 
ADHD umbrella (Loe, 2008). This is largely a result of pharmacological commercialization. 
Direct-to-consumer drug advertisement first emerged in the 1980s, starting with Merck in 1981 
as it ran print advertisements for the flu vaccine. In 1983, Boots Pharmaceuticals launched the 
first broadcast ad to promote prescription ibuprofen (Ventola, 2011). Prior to this, prescription 
drugs were not allowed to be advertised on TV. Commercialization makes the drugs seem less 
harmful or lower risk, especially when their ads pop up between those of benign household 
products. Prescription medications become just another item to add to the shopping cart. It is 
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telling that pharmaceutical companies spend twice as much on advertising as they do on research 
(Angell, 2004). The normalization of drugs makes accepting a prescription that much easier.  
Of course, direct-to-consumer pharmaceutical marketing can be helpful to those who 
might not otherwise know of their condition. Some lower-income neighborhoods may lack the 
resources necessary to recognize signs or symptoms of an otherwise treatable condition 
(Bergner, 1968). Thus, seeing a print ad or watching a commercial can be informative. 
Pharmaceutical marketing only becomes harmful when it convinces those who do not have a 
disorder to believe they do. This is especially prevalent with ADHD, where behavioral traits of 
hyperactivity and inattentiveness are present on a continuum in all individuals. When 
commercials list symptoms that are present in ​everyone​ to some degree, consumers may be 
prompted to self-diagnose. In this respect, these commercials are “selling sickness” (Moynihan, 
2005), and consumers may define their troublesome behaviors as disorders.  
In our increasingly competitive society, students are especially susceptible to such 
marketing ploys. They often seek doctor consultations in hopes of attaining a prescription for 
psychostimulants in effort to boost SAT scores and GPA; those who are denied may pursue other 
routes of obtaining the pills illegally. This explains the burgeoning “grey market,” in which 
psychostimulants are sold to students without diagnosed disorders during exam periods (Loe, 
2008). Risks to the user aside, this abuse undermines the validity of the disorder for those who 
are truly struggling. And the use of such medication without real need - even ​with​ a doctor’s 
prescription - shares the same risks.  
Potential for Abuse and Long-term Risks 
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As with all drugs, it is important not to underestimate a psychostimulant’s potential for 
abuse just because it is associated with education and learning. Psychostimulants are classified 
by the DEA as Schedule II Substances, which rates their potential for addiction on par with drugs 
such as oxycodone and methamphetamine (Drug Enforcement Administration, 2019). Patients 
must adhere to their prescriptions and follow strict instructions regarding what to do if they miss 
a pill, need a dosage adjustment, or anything in relation to the drug use. Additionally, heavy use 
of psychostimulants like Adderall over long periods of time can increase the user’s potential for 
long-term side effects and risk factors (Lautieri, 2019). These can range from minor headaches to 
to serious heart palpitations (Lakhan, 2012). And because many people start the medications as 
children, adult patients may require an updated risk analysis from a doctor before they are able to 
make informed decisions about continued use.  
Psychostimulants as Treatment 
The most important ethical point to consider when using psychostimulants to treat ADHD 
is whether the medication is being used correctly. Psychostimulants have proven to be useful and 
even necessary for some people with ADHD to function in school and employment. In one 
study, the use of psychostimulant medication in combination with diligent study habits in 
undergraduates with ADHD was sufficient to eliminate the GPA disparity between students with 
ADHD and students without (Advokat, 2013). In other cases, medication is not necessary - or at 
least not as the first step. Pharmaceuticalization can promote the idea that medication is the ​only 
treatment - negating the exploration of alternative solutions before resorting to pills. For ADHD 
specifically, it has been found that interventions as simple as exercising 30 minutes a day and 
reducing sugar intake can mitigate symptoms (Grassmann, 2014). Alternative scientific 
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approaches include EEG biofeedback, in which brain waves are met with feedback to promote 
activity in other areas to help people “control” the way they concentrate. This resulted in nearly 
80% improvement in standardized testing, IQ scores, and parent/teacher ratings of the children’s 
behavior (Fox, 2005). Behavior modification via operant conditioning and positive reinforcement 
also significantly reduced ADHD tendencies in schoolchildren (Hodgson, 2012). Pharmaceutical 
commercialization can act as a vessel for increasing diagnoses and increased medication seeking 
without first pursuing other options. 
Delayed Development vs. Disorder 
It is also important to determine whether we are medicating symptoms of what might be 
perfectly normal psychological or behavioral patterns in a child with delayed development. That 
is, a child who is transiently below the age group’s physical or mental development curve. 
Children slow to develop language and literacy skills may seem to have lower attention spans, 
when really the task is more mentally taxing for them compared to their peers and requires 
higher levels of exertion (National Research Council, 2015). The manifestation can then be 
confused with ADHD. Slow cognitive development can be caused by a variety of factors. Living 
in a neighborhood where children can play unaccompanied by a parent vs. living in a 
neighborhood where the children cannot can effect the children's motor, social and behavioral 
skills - with the latter group scoring lower in all three categories (Hüttenmoser, 1995). Infants 
born small for gestational age (SGE) with respect to smaller weight, length, and head size have 
slower rates of development throughout childhood and early adulthood (Clayton, 2007). This 
includes slower cognitive development, which may present as ADHD (Indredavik, 2004). So 
how can we tell the difference? One solution is to screen children for physical underdevelopment 
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- which often goes hand-in-hand with cognitive development (National Research Council, 2015). 
This would allow clinicians to effectively rule out underdevelopment before reaching for the 
prescription pad.  
Additionally, an estimated 30% of children with ADHD exhibit comorbid learning and 
psychological impairments such as dyslexia, antisocial disorders, or even anxiety (Biederman, 
1993; Seidman, 2005). While medical professionals see the rising incidence rate as a growing 
clinical problem, sociologists see it as a social crisis about how we define “normal” childhood 
behavior and academic achievement. At the heart of this debate lies the rights of a child to be 
“raised” and seen as a person, rather than “designed.” While ​raising​ children employs 
neuroscience to maximize educational benefits, ​designing​ children uses neuroscience to achieve 
a desirable disposition of the child; made possible by psychostimulants (Stein, 2010). As such, it 
is important to understand that while medications treat the ​symptoms​, further investigation is 
needed to find the source of the problem and address it properly for the wellbeing of the child - 
and not for his parent or teacher. 
It could be argued that valuable time may be wasted, perhaps deferring years of necessary 
treatment, by relegating pharmacological symptom management to a last resort. One can see the 
questioning parents of a child with bona fide ADHD questioning a physician as to why their 
child was forced to endure the difficulties of such a condition for so long when drugs were 
readily available to address the child’s symptoms. Such is the risk of exploring other, less 
intrusive options before opting for medication, which in some cases may have been the right 
approach all along. This is where the judgement of the physician or psychoanalyst comes into 
play. It should be noted, especially in considering the above, that my position is not in opposition 
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to the medications themselves, but rather to their exploitation and unnecessary use. Turning 
health and medicine into a commodity undermines the seriousness of taking prescription drugs.  
Social Pharmacology as a Compromise 
A solution to this diagnostic conflict may reside within social pharmacology. Social 
pharmacology is a multidisciplinary system that analyzes social and cultural influence on drug 
use and effects (Montagne, 2004). Its main goal is to maximize patient therapy benefits and 
minimize negative social consequences. It goes beyond merely contrasting patient symptoms 
with drug risks and rewards, and into the contextualization of patient concerns within their social 
environments. This holistic approach can curb the tendency to immediately choose pills without 
first pursuing other options, in addition to making sure that the right pills are prescribed for the 
right reason.  
Conclusion 
Pharmaceutical commercialization has expanded the realm of medicine and arguably 
contributed to lowering consumer tolerance for psychiatric discomfort. However, pharmaceutical 
marketing does not exist in a vacuum. Consumers cannot obtain advertised prescription 
medications on their own - they must first consult with a primary care provider or psychiatric 
specialist. As such, clinicians should only turn to psychostimulant prescription after all other 
options have been exhausted: alternative interventions, psychotherapy, and screenings for 
co-exhibited conditions like dyslexia, depression, and anxiety. Some patients really do need and 
benefit from ADHD medication, but it must be used wisely. Future work in ethics should 
emphasize that any drug intervention, no matter how small, is still a drug. American health 
sciences should shift toward social pharmacology over traditional pharmacology, which 
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incorporates various disciplines to increase safety, efficacy, and knowledge of marketed drug use 
instead of first treating symptoms with drugs. In the end, it is unethical to deploy pharmacology 
to artificially change behavior in children primarily for the convenience of the parent, doctor, or 
educator. In medicine, ethics must always supersede accommodation.  
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ADHD: Too 
Much Too Soon?
The Implications of Medication Use to Manage 
ADHD Diagnoses By: Brooke Schaeffer
Thomas is a fifth grade boy. He loves to learn and 
share what he learns with others. Although he is 
bright, Thomas cannot sit still in class, chats with 
his neighbors, and cannot get his work done on 
time. This lead his teacher to meet with Thomas’ 
parents, where she mentioned the possibility of 
Attention Deficit Hyperactivity Disorder (ADHD). 
Thomas’ parents brought him to a psychiatrist who 
suggested that Thomas take Adderall. Although his 
parents do not want to put him on mind-altering 
drugs at such a young age, what else is to be done 
when behavior gets in the way of academic 
performance? Thomas’ scenario is becoming 
increasingly common across the United States. 
Over the past few decades, the U.S. has seen a 
dramatic increase in ADHD diagnoses, and with 
them a rise in the prescribing of psychostimulant 
medications. From Ritalin to Adderall, the American 
youth is ingesting a staggering amount of 
medication. But what are the long-term effects of 
taking such powerful drugs, and at such a young 
age? How can we be sure that a child really has 
ADHD and is not just a slow developer? These 
questions are our central focus as we apply a 
critical lens to the ethicality of attention deficit 
diagnoses and treatments in America. 
What is ADHD?
According to the DSM-5, ADHD is defined as a 
group of behavioral problems related to 
inattentiveness, impulsivity, and hyperactivity. To 
have the disorder, one must display at least six 
1
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symptoms from a behavioral checklist of 18 criteria. 
ADHD is currently the most commonly diagnosed 
and treated disorder among American youth6. But 
what is the difference between a psychiatric 
disorder, and a medical disease? Dr. Mary Ann 
Block of the Block Institute explains that ADHD is a 
psychiatric label for symptoms such as fidgeting, 
blurting out answers, and inability to complete 
work on time: not a medical disease. She argues 
that sticking children with the title “ADHD” shifts 
focus away from identifying the true underlying 
conditions behind the symptoms. Many children 
with ADHD are known to exhibit comorbidity with 
other more serious learning and psychological 
impairments such as dyslexia, antisocial disorders, 
or even anxiety. As such, it is important to 
understand that medications treat the symptoms, 
but further investigation is needed to find the 
source of the problem and address it properly. 
Environmental Influence on Diagnosis
Rather than playing with wooden blocks and simple 
figurines, today’s children are inundated with 
sensory information from tablets, smart phones, 
and other technology. Even children’s television 
shows have complexified over time to become rife 
with sensory overload. In the past decade alone, 
we have seen the atmosphere of kid’s programming 
Biological Effects of Drug Treatment
As of 2016, 9.4% of children in the US between
the ages of 2 and 17 had diagnosed cases of 
ADHD. 5.2% of US children take psychostimulant 
medication such as Methylphenidate (Ritalin) and 
amphetamine (Adderall) to manage it. These 
medications are classified by the DEA as a 
Schedule II Substances. Because of their 
psychotropic properties, they share the same 
category as opium, oxycodone, and morphine, 
and are rated as having a “high potential for 
abuse.” Now, by no means am I directly equating 
a few milligrams of Adderall to a dose of 
morphine. But it is important to remember that 
even though these ADHD medications are meant 
to help children with school, they are still drugs 
and have the potential for abuse. On a biological 
level, psychostimulant medications work by 
blocking dopamine reuptake in the brain, allowing 
dopamine levels of an ADHD patient to reach 
those of a normal student. The drugs operate as 
both central nervous system stimulants and 
cardiovascular stimulants. In a 2013 study, Dr. 
Nora Volkow did a one-year imaging study on the 
brains of patients before and after taking Ritalin 
“The United States 
consumes between 80 
and 90% of the Ritalin 
prescribed today. ” 
– Dr. Richard Degrandpre 6
55%
45%
Use of Medication in 
ADHD Patients
Use medication No medication
Chart: 9.4% of children in the US ages of 2-
17 have been diagnosed. Of that 
population, 55% of children take daily 
medication to manage the disorder. 
shift from the calming, interactive critical thinking 
experience of “Blue’s Clues,” to unrelenting 
bombardments of colors, sounds effects, and 
exaggerated movements, and screaming such as on 
Cartoon Network. After growing up in a such an 
overly-stimulating environment, the comparative 
tedium of the classroom seems unbearable, and 
practically breeds rambunctiousness and 
inattentiveness in young students. Could this be a 
contributing factor in the rise of ADHD diagnoses? 
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Case Study: Should we treat technology as a contributing factor to ADHD?
Parker is six years old and entering the first grade. From ages two 
through six, her father worked from home, and often sat her in front 
of the TV for hours to keep her entertained. When Parker grew bored 
of cartoons, he downloaded kid-friendly games on his iPad to keep her 
occupied. One harmful outcome from this over-exposure to tech 
stimulation is that by the time Parker reaches first grade, she has 
become extremely reliant on high levels of stimulation to engage with 
material. Unable to focus, she is put on the ADHD candidate list. 
However, Parker’s dad downloaded mostly educational games on the 
iPad. So although Parker has trouble focusing on the comparatively 
mundane classwork tasks, she is always ahead of her classmates in 
reading and writing skills. This situation prompts the question of what 
is most valuable to children Parker’s age? Academic advancement 
courtesy of technology, at the expense of attention span and social 
couth, or being more psychologically acclimated to the classroom 
environment and better adapted to socially interact? 
pursue pharmacological remedies satisfied that 
they explored less drastic options first. If these 
other approaches do not seem to help, Thomas 
should start a low dose of Adderall as prescribed 
by the doctor. Monitor him for side effects, and 
make him aware that this medication is not just 
another vitamin he takes each morning. So long 
as Thomas and his parents are mindful of his 
Adderall use and engaging in informed consent, 
there should be no concern about medication 
abuse. This of course, is just my opinion. But 
taking a step back to consider the country’s youth 
as a whole and the rise of ADHD, I leave you with 
some parting questions: How can these various
Image source: medicaldaily.com
for one year. Post-treatment results showed an 
increased density of dopamine transporters, 
which are responsible for removing dopamine 
from the brain. This response to the medication’s 
artificial increase in dopamine may cause a 
gradual need for increased dosage over time to 
achieve the same effects. Additionally, if the 
patient were to come off the medication, they 
develop a dopamine deficiency and run into other 
issues like depression. 
Concluding Remarks
Looking back to the beginning of this article, 
Thomas’ parents were faced with a difficult 
choice: either medicate their child to manage his 
classroom behavior, or withhold from medication 
and hope that his behavior improves over time. To 
this dilemma, I suggest a two-layered approach. 
First, ask the psychiatrist to pursue some non-drug 
related approaches. Behavior therapy has been 
proven an effective alternative to 
psychostimulants, and works well for many ADHD 
patients. One downside to this conservative 
approach is that because therapy is not 
guaranteed to work, this route may delay Thomas’ 
improvement and cause him to continue to suffer
academically. However, it allows his parents to 
Baseline After 1 Year
PET scan of dopamine transporter 
concentrations in ADHD patient before and 
after taking psychostimulant medication12. 
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medications affect a child’s autonomy at such a 
young age? And what happens 
when, if ever, the meds stop, and underlying 
psychological causes or triggers remain? The future 
of America’s children is up to our readers. Before 
you turn to pills, or any medication for a simple 
solution, I urge you to ask yourself: how much do 
you really know? Future generations deserve a 
more clear answer.
